Loading patent…
AssigneesShimadzu Corporation, Hyogo College of Medicine, Educational Corporation Mukogawa Gakuin
InventorsEiichi Matsuo, Naoki Kaneko, Makoto Watanabe, Osamu Nishimura, Noboru Okamura, Akinobu Gotoh
Estimating the term…
The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.
A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and α-enolase.
Galectin-1 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging.
Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging.
A combination of Galectin-1 and Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging.
α-Enolase as a blood marker for renal cancer for use in an examination performed before diagnostic imaging.
α-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.
A renal cancer marker detection kit comprising an enzyme-labeled α-enolase antibody.
A method for analyzing a renal cancer marker in a collected blood sample, the method comprising the step of acquiring a level of a renal cancer marker selected from the group consisting of Galectin-1, Galectin-3, and α-enolase in a collected blood sample derived from an individual, and evaluating the acquired marker level based on whether said acquired marker level is higher or lower than a reference level of the renal cancer marker.
Dependencies are inferred from the claim text.